Premium
Incidence, risk factors, and long‐term outcomes associated with antibody‐mediated rejection — The long‐term Deterioration of Kidney Allograft Function (DeKAF) prospective cohort study
Author(s) -
Hart Allyson,
Schladt David P.,
Matas Arthur J.,
Itzler Robbin,
Israni Ajay K.,
Kasiske Bertram L.
Publication year - 2021
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.14337
Subject(s) - medicine , hazard ratio , prospective cohort study , renal function , kidney transplantation , incidence (geometry) , confidence interval , cohort , cohort study , panel reactive antibody , proportional hazards model , kidney , transplantation , urology , physics , optics
Major gaps remain in our understanding of antibody‐mediated rejection (AMR) after kidney transplant. We examined the incidence, risk factors, response to treatment, and effects on outcomes of AMR at seven transplant programs in the long‐term Deterioration of Kidney Allograft Function prospective study cohort. Among 3131 kidney recipients, there were 194 observed AMR cases (6.2%) during (mean ± SD) 4.85 ± 1.86 years of follow‐up. Time to AMR was 0.97 ± 1.17 (median, 0.48) years. Risk factors for AMR included younger recipient age, human leukocyte antigen DR mismatches, panel‐reactive antibody >0%, positive T‐ or B‐cell cross‐match, and delayed graft function. Compared with no AMR, the adjusted time‐dependent hazard ratio for death‐censored graft failure is 10.1 (95% confidence interval, 6.5‐15.7) for all AMR patients, 4.0 (2.5, 9.1) for early AMR (<90 days after transplant), and 24.0 (14.0‐41.1) for late AMR (≥90 days after transplant). Patients were treated with different therapeutic combinations. Of 194 kidney transplant recipients with AMR, 50 (25.8%) did not respond to treatment, defined as second AMR within 100 days or no improvement in estimated glomerular filtration rate by 42 days. Long‐term outcomes after AMR are poor, regardless of the initial response to treatment. Better prevention and new therapeutic strategies are needed to improve long‐term allograft survival.